Related references
Note: Only part of the references are listed.Ibrexafungerp: A novel oral glucan synthase inhibitor
M. R. Davis et al.
MEDICAL MYCOLOGY (2020)
In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Genotyping Reveals High Clonal Diversity and Widespread Genotypes of Candida Causing Candidemia at Distant Geographical Areas
Jesus Guinea et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)
M. C. Arendrup et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis
Nkechi Azie et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
A Novel 1,3-Beta-D-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis
E. L. Larkin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Clonal spread and azole-resistant mechanisms of non-susceptible Candida albicans isolates from vulvovaginal candidiasis patients in three Shanghai maternity hospitals
YongQin Wu et al.
MEDICAL MYCOLOGY (2018)
The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.
Laura Judith Marcos-Zambrano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates
Tchana Martinez Brandolt et al.
BRAZILIAN JOURNAL OF MICROBIOLOGY (2017)
Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species
Michael A. Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2016)
Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China
Jin-Yan Liu et al.
RESEARCH IN MICROBIOLOGY (2015)
Determination of Isavuconazole Susceptibility of Aspergillus and Candida Species by the EUCAST Method
Susan J. Howard et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)
Maiken C. Arendrup et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Share Paper
